- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Icosapent Ethyl helps achieve coronary plaque regression in CAD: EVAPORATE trial
USA: Treatment of coronary atherosclerosis patients with icosapent ethyl (IPE) helped to achieve significant regression of low attenuation plaque (LAP) volume on multidetector computed tomography (MDCT), according to results from the EVAPORATE trial. The findings were presented at the European Society of Cardiology (ESC) Congress 2020 and concurrently published in the European Heart Journal.
Despite treatment with statins for reducing cardiovascular events and slowing the progression of coronary atherosclerosis, there remains a significant cardiovascular risk. Icosapent ethyl (Vascepa) is a highly purified eicosapentaenoic acid ethyl ester which when added to a statin was shown to reduce CV events by 25% and total CV events by 32% in the REDUCE-IT trial. The mechanics of benefits were however not fully experienced.
The EVAPORATE trial by Matthew J Budoff, Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA, USA, and colleagues sought to determine whether IPE 4 g/day given in addition to statin and diet, would result in a greater change from baseline in plaque volume, measured by serial MDCT, than placebo in statin-treated patients.
A total of 80 patients were enrolled in this randomized, double-blind, placebo-controlled trial. Conditions for inclusion -- the presence of coronary atherosclerosis as documented by MDCT (one or more angiographic stenoses with ≥20% narrowing), having persistently elevated triglyceride (TG) levels, and on statin therapy. They underwent an interim scan at 9 months and a final scan at 18 months with coronary computed tomographic angiography.
The pre-specified primary endpoint was changed in LAP volume at 18 months between IPE and placebo groups.
Key findings of the study include:
- Baseline demographics, vitals, and laboratory results were not significantly different between the IPE and placebo groups; the median TG level was 259.1 ± 78.1 mg/dL.
- There was a significant reduction in the primary endpoint as IPE reduced LAP plaque volume by 17%, while in the placebo group LAP plaque volume more than doubled (+109%).
- There were significant differences in rates of progression between IPE and placebo at study end involving other plaque volumes including fibrous, and fibrofatty (FF) plaque volumes which regressed in the IPE group and progressed in the placebo group.
- When further adjusted for age, sex, diabetes status, hypertension, and baseline TG, plaque volume changes between groups remained significantly different.
- Only dense calcium did not show a significant difference between groups in multivariable modelling.
"Icosapent ethyl demonstrated significant regression of LAP volume on MDCT than placebo over 18 months. The trial provides important mechanistic data on plaque characteristics that may have relevance to the REDUCE-IT results and clinical use of IPE," concluded the authors.
The study, "Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial," is published in the European Heart Journal.
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751